Milnacipran for SSRI-intolerant patients with premenstrual dysphoric disorder

Primary Psychiatry

Volumn 12, Issue 9, 2005, Pages 28-29

  Ginsberg, David L ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPROPANE DERIVATIVE; CYTOCHROME P450; FLUVOXAMINE; MILNACIPRAN; NORADRENALIN; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; CASE REPORT; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR DEPRESSION; NAUSEA; NORADRENALIN UPTAKE; PREMENSTRUAL DYSPHORIC DISORDER; REVIEW; SEROTONIN UPTAKE; SOMNOLENCE;

EID: 25444524037     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (4)

1. Yonkers KA. Antidepressants in the treatment of premenstrual dysphoric disorder. J Clin Psychiatry. 1997;58(Suppl 14):4-10; discussion 11-3.
2. Spencer CM, Wilde MI. Milnacipran. A review of its use in depression. Drugs. 1998;56(3):405-427.
3. Cypress Completes Enrollment of Phase III Milnacipran Clinical Trial Results Expected Fall 2005. Available at: http://www.globeinvestor.com/servlet/ WireFeedRedirect?cf=GlobeInv estor/config&vg=BigAdVariableGenerator&dat e=20041208&archive=bwire&slug=200412080 05327. Accessed August 17, 2005.
4. Yamada K, Kanba S. Effectiveness of milnacipran for SSRI-intolerant patients with premenstrual dysphoric disorder. J Clin Psychopharmacol. 2005;25(4):398-399.